急性脑梗死应用尿激酶静脉溶栓治疗目前已在国内外基本普及,而且疗效肯定,但应用尿激酶溶栓后可发生再梗死。我们采用尿激酶(uk)加用低分子肝素和单纯用uk溶栓治疗,进行对照观察,观察其疗效和再梗死发生率。现报告如下。1 资料与方法1.1 病例入选标准 ①系脑梗死(包括脑血栓形成及脑梗死病人),符合全国第4届脑血管病学术会议制订的缺血性脑血管病诊断标准;②发病≤6h;③年龄18～75岁,性别不限;④无昏迷;⑤头颅CT证实无颅内出血者;⑤无出血性病史和出血倾向者:出凝血时间正常,血小板计数>100× Urokinase intravenous thrombolytic therapy of acute cerebral infarction has been basically universal at home and abroad, and the curative effect is affirmed, but reinfusion after urokinase thrombolytic therapy may occur again. We use urokinase (uk) plus low molecular weight heparin and uk thrombolytic therapy, the control observation, observation of its efficacy and incidence of reinfarction. The report is as follows. 1 Materials and Methods 1.1 Case Selection criteria ① Department of cerebral infarction (including patients with cerebral thrombosis and cerebral infarction), in line with the Fourth National Conference on Cerebrovascular Disease developed diagnostic criteria of ischemic cerebrovascular disease; ② onset ≤ 6h; ③ Age 18 to 75 years of age, gender is not limited; ④ no coma; ⑤ cranial CT confirmed no intracranial hemorrhage; ⑤ no history of bleeding and bleeding tendencies: out of normal clotting time, platelet count> 100